Publications
Detailed Information
Desmopressin is an Effective Treatment for Mixed Nocturia with Nocturnal Polyuria and Decreased Nocturnal Bladder Capacity
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hye Won | - |
dc.contributor.author | Choo, Myung-Soo | - |
dc.contributor.author | Lee, Jeong Gu | - |
dc.contributor.author | Park, Choal Hee | - |
dc.contributor.author | Lee, Jeong Zoo | - |
dc.contributor.author | Park, Won Hee | - |
dc.contributor.author | Lee, Kyu-Sung | - |
dc.contributor.author | Han, Deok Hyun | - |
dc.contributor.author | Paick, Jae-Seung | - |
dc.date.accessioned | 2012-06-14T06:04:43Z | - |
dc.date.available | 2012-06-14T06:04:43Z | - |
dc.date.issued | 2010-12 | - |
dc.identifier.citation | JOURNAL OF KOREAN MEDICAL SCIENCE; Vol.25 12; 1792-1797 | ko_KR |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | https://hdl.handle.net/10371/77068 | - |
dc.description.abstract | To investigate the efficacy and safety of desmopressin in patients with mixed nocturia, Patients aged >= 18 yr with mixed nocturia (>= 2 voids/night and a nocturnal polyuria index [NPi] >33% and a nocturnal bladder capacity index [NBCi] >1) were recruited. The optimum dose of oral desmopressin was determined during a 3-week dose-titration period and the determined dose was maintained for 4 weeks. The efficacy was assessed by the frequency-volume charts and the sleep questionnaire. The primary endpoint was the proportion of patients with a 50% or greater reduction in the number of nocturnal voids (NV) compared with baseline. Among 103 patients enrolled, 94 (79 men and 15 women) were included in the analysis. The proportion of patients with a 50% or greater reduction in NV was 68 (72%). The mean number of NV decreased significantly (3.20 to 1.34) and the mean nocturnal urine volume, nocturia index, NPi, and NBCi decreased significantly. The mean duration of sleep until the first NV was prolonged from 118.4 +/- 44.1 to 220.3 +/- 90.7 min (P<0.001). The overall impression of patients about their quality of sleep improved. Adverse events occurred in 6 patients, including one asymptomatic hyponatremia. Desmopressin is an effective and well-tolerated treatment for mixed nocturia. | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | ko_KR |
dc.subject | Urinary Bladder | ko_KR |
dc.subject | Deamino Arginine Vasopressin | ko_KR |
dc.subject | Nocturnal Polyuria | ko_KR |
dc.subject | Nocturia | ko_KR |
dc.subject | Hyponatremia | ko_KR |
dc.title | Desmopressin is an Effective Treatment for Mixed Nocturia with Nocturnal Polyuria and Decreased Nocturnal Bladder Capacity | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 이혜원 | - |
dc.contributor.AlternativeAuthor | 주명수 | - |
dc.contributor.AlternativeAuthor | 이정구 | - |
dc.contributor.AlternativeAuthor | 박철희 | - |
dc.contributor.AlternativeAuthor | 백재승 | - |
dc.contributor.AlternativeAuthor | 이정주 | - |
dc.contributor.AlternativeAuthor | 한덕현 | - |
dc.contributor.AlternativeAuthor | 박원희 | - |
dc.contributor.AlternativeAuthor | 이규성 | - |
dc.identifier.doi | 10.3346/jkms.2010.25.12.1792 | - |
dc.citation.journaltitle | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.description.citedreference | Choo MS, 2008, NEUROUROL URODYNAM, V27, P60, DOI 10.1002/nau.20458 | - |
dc.description.citedreference | van Kerrebroevk P, 2007, EUR UROL, V52, P221, DOI 10.1016/j.eururo.2007.01.027 | - |
dc.description.citedreference | Bae JH, 2007, J UROLOGY, V178, P200, DOI 10.1016/j.juro.2007.03.042 | - |
dc.description.citedreference | Chen FY, 2007, INT UROGYNECOL J, V18, P431, DOI 10.1007/s00192-006-0167-x | - |
dc.description.citedreference | Irwin DE, 2006, EUR UROL, V50, P1306, DOI 10.1016/j.eururo.2006.09.019 | - |
dc.description.citedreference | Bing MH, 2006, BJU INT, V98, P599, DOI 10.1111/j.1464-410X.2006.06390.x | - |
dc.description.citedreference | Weiss JP, 2006, J UROLOGY, V175, pS16, DOI 10.1016/S0022-5347(05)00312-5 | - |
dc.description.citedreference | Marinkovic SP, 2004, BRIT MED J, V328, P1063 | - |
dc.description.citedreference | Iwasaki H, 2004, UROLOGY, V63, P994, DOI 10.1016/j.urology.2003.11.036 | - |
dc.description.citedreference | Weatherall M, 2004, NEUROUROL URODYNAM, V23, P302, DOI 10.1002/nau.20038 | - |
dc.description.citedreference | NAM S, 2004, KOREAN J UROL, V45, P49 | - |
dc.description.citedreference | Rembratt A, 2003, BJU INT, V91, P642 | - |
dc.description.citedreference | WEISS JP, 2003, CURR UROL REP, V4, P362 | - |
dc.description.citedreference | Mattiasson A, 2002, BJU INT, V89, P855 | - |
dc.description.citedreference | van Kerrebroeck PEV, 2002, BJU INT, V89, P420 | - |
dc.description.citedreference | van Kerrebroeck P, 2002, NEUROUROL URODYNAM, V21, P179, DOI 10.1002/nau.10053 | - |
dc.description.citedreference | KIM ET, 2001, KOREAN J UROL, V42, P1075 | - |
dc.description.citedreference | Asplund R, 1999, BJU INT, V83, P591 | - |
dc.description.citedreference | Asplund R, 1998, BRIT J UROL, V82, P642 | - |
dc.description.citedreference | Rittig S, 1998, CLIN ENDOCRINOL, V48, P235 | - |
dc.description.citedreference | Lethagen S, 1998, AM J HEMATOL, V57, P153 | - |
dc.description.citedreference | Weiss JP, 1998, NEUROUROL URODYNAM, V17, P467 | - |
dc.description.citedreference | Malmsten UGH, 1997, J UROLOGY, V158, P1733 | - |
dc.description.citedreference | Nadal M, 1996, EUR J ENDOCRINOL, V134, P174 | - |
dc.description.citedreference | ASPLUND R, 1992, SCAND J PRIM HEALTH, V10, P98 | - |
dc.description.citedreference | VILHARDT H, 1990, DRUG INVEST S5, V2, P2 | - |
dc.description.citedreference | BELMAKER RH, 1986, MIL MED, V151, P660 | - |
dc.description.citedreference | BLOK C, 1986, J UROLOGY, V136, P1123 | - |
dc.description.citedreference | KIRKLAND JL, 1983, BRIT MED J, V287, P1665 | - |
dc.description.citedreference | THOMAS S, 1957, J PHYSIOL-LONDON, V139, P337 | - |
dc.description.tc | 1 | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.